Drug intelligence / Profile preview

Achromobacter spp. bacteriophage 2001248D

Development stage: Preclinical
Lead developer: Mikroliz
Administration: Intravenous, Inhalation

Overview

Achromobacter spp. bacteriophage 2001248D is a lytic bacteriophage developed by Mikroliz (Mikroliz Therapeutic Bacteriophage Bank) for the potential treatment of bacterial infections caused by Achromobacter species. It is maintained in Mikroliz's extensive library of therapeutic bacteriophages, which are intended for personalized clinical phage therapy against multi-drug resistant pathogens. The phage specifically targets and lyses Achromobacter host cells, offering a potential therapeutic option where conventional antibiotic treatments are ineffective.

Beyond the preview

Go deeper on Achromobacter spp. bacteriophage 2001248D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achromobacter spp. bacteriophage 2001248D.

Explore the full profile